<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>9922228</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmid">36370302</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmc">9922228</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="publisher-id">744</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="doi">10.1007/s11682-022-00744-4</article-id></all-ids><extracted-table><table-id>Tab1</table-id><table-label>Table 1</table-label><table-caption>Demographic, clinical, and neuropsychological measures of patients, divided into pseudobulbar (PSB) and non-pseudobulbar (nPSB), and healthy controls (HC); data are shown as mean (standard deviation) or count (percentage)
</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab1"><label>Table 1</label><caption><p>Demographic, clinical, and neuropsychological measures of patients, divided into pseudobulbar (PSB) and non-pseudobulbar (nPSB), and healthy controls (HC); data are shown as mean (standard deviation) or count (percentage)
</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variables</th><th align="left">HC<break/>(<italic>n</italic> = 26)</th><th align="left">ALS<break/>(<italic>n</italic> = 27)</th><th align="left">PSB<break/>(<italic>n</italic> = 13)</th><th align="left">nPSB<break/>(<italic>n</italic> = 14)</th><th align="left">HC vs ALS<break/>p-value</th><th align="left">PSB vs nPSB<break/>p-value</th></tr></thead><tbody><tr><td align="left">Age, years</td><td align="left">58 (12)</td><td align="left">58 (9)</td><td align="left">56 (9)</td><td align="left">60 (10)</td><td align="left">0.947</td><td char="." align="char">0.271</td></tr><tr><td align="left">Education, years</td><td align="left">11 (4)</td><td align="left">11 (4)</td><td align="left">9 (3)</td><td align="left">12 (5)</td><td align="left">0.824</td><td char="." align="char">0.134</td></tr><tr><td align="left">Sex, male</td><td align="left">20 (76.9%)</td><td align="left">23 (85.2%)</td><td align="left">11 (84.6%)</td><td align="left">12 (85.7%)</td><td align="left">0.453</td><td char="." align="char">0.328</td></tr><tr><td align="left">Disease Duration, months</td><td align="left">n.a</td><td align="left">21 (21)</td><td align="left">16 (17)</td><td align="left">25 (25)</td><td align="left">n.a</td><td char="." align="char">0.24</td></tr><tr><td align="left"><p>Disease onset</p><p>(bulbar/upper limbs/lower limbs)</p></td><td align="left">n.a</td><td align="left">5/10/12</td><td align="left">4/5/4</td><td align="left">1/5/8</td><td align="left">n.a</td><td char="." align="char">0.157</td></tr><tr><td align="left"><p>Disease phenotype</p><p>(classic/bulbar/FL/FA/pyramidal)</p></td><td align="left">n.a</td><td align="left">3/3/5/5/11</td><td align="left">2/2/1/3/5</td><td align="left">1/1/4/2/6</td><td align="left">n.a</td><td char="." align="char">0.332</td></tr><tr><td align="left">ALSFRS-R total score</td><td align="left">n.a</td><td align="left">43 (3)</td><td align="left">42 (4)</td><td align="left">43 (3)</td><td align="left">n.a</td><td char="." align="char">0.773</td></tr><tr><td align="left">Bulbar subscore</td><td align="left">n.a</td><td align="left">11 (1)</td><td align="left">11 (1)</td><td align="left">12 (1)</td><td align="left">n.a</td><td char="." align="char"><bold>0.031</bold></td></tr><tr><td align="left">Fine motor subscore</td><td align="left">n.a</td><td align="left">10 (2)</td><td align="left">10 (2)</td><td align="left">10 (2)</td><td align="left">n.a</td><td char="." align="char">0.599</td></tr><tr><td align="left">Gross motor subscore</td><td align="left">n.a</td><td align="left">10 (2)</td><td align="left">10 (2)</td><td align="left">9 (2)</td><td align="left">n.a</td><td char="." align="char">0.147</td></tr><tr><td align="left">Respiratory subscore</td><td align="left">n.a</td><td align="left">12 (0.4)</td><td align="left">12 (0.6)</td><td align="left">12 (0)</td><td align="left">n.a</td><td char="." align="char">0.221</td></tr><tr><td align="left">UMN score</td><td align="left">n.a</td><td align="left">8 (4)</td><td align="left">8 (4)</td><td align="left">8 (5)</td><td align="left">n.a</td><td char="." align="char">0.778</td></tr><tr><td align="left">King’s clinical staging (1/2/3)*</td><td align="left">n.a</td><td align="left">11/13/3</td><td align="left">5/5/3</td><td align="left">6/8/0</td><td align="left">n.a</td><td char="." align="char">0.305</td></tr><tr><td align="left">MMSE</td><td align="left">29(1)</td><td align="left">n.a</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">ECAS total score</td><td align="left">n.a</td><td align="left">88 (25)</td><td align="left">83 (22)</td><td align="left">92 (27)</td><td align="left">n.a</td><td char="." align="char">0.326</td></tr><tr><td align="left">Language</td><td align="left">n.a</td><td align="left">21 (5)</td><td align="left">20 (4)</td><td align="left">22 (5)</td><td align="left">n.a</td><td char="." align="char">0.441</td></tr><tr><td align="left">Verbal fluency</td><td align="left">n.a</td><td align="left">16 (7)</td><td align="left">16 (7)</td><td align="left">16 (8)</td><td align="left">n.a</td><td char="." align="char">0.993</td></tr><tr><td align="left">Executive functions</td><td align="left">n.a</td><td align="left">27 (11)</td><td align="left">24 (11)</td><td align="left">29 (11)</td><td align="left">n.a</td><td char="." align="char">0.269</td></tr><tr><td align="left">Memory</td><td align="left">n.a</td><td align="left">13 (5)</td><td align="left">12 (5)</td><td align="left">14 (5)</td><td align="left">n.a</td><td char="." align="char">0.205</td></tr><tr><td align="left">Visuospatial abilities</td><td align="left">n.a</td><td align="left">11 (1)</td><td align="left">10 (1)</td><td align="left">11 (1)</td><td align="left">n.a</td><td char="." align="char">0.214</td></tr><tr><td align="left">CNS-LS</td><td align="left">n.a</td><td align="left">12 (4)</td><td align="left">16 (2)</td><td align="left">9 (2)</td><td align="left">n.a</td><td char="." align="char"><bold> &lt; 0.001</bold></td></tr><tr><td align="left">Laughing</td><td align="left">n.a</td><td align="left">7 (3)</td><td align="left">9 (3)</td><td align="left">5 (1)</td><td align="left">n.a</td><td char="." align="char"><bold> &lt; 0.001</bold></td></tr><tr><td align="left">Crying</td><td align="left">n.a</td><td align="left">5 (2)</td><td align="left">6 (2)</td><td align="left">4 (1)</td><td align="left">n.a</td><td char="." align="char"><bold>0.003</bold></td></tr><tr><td align="left">BDI-II</td><td align="left">n.a</td><td align="left">7 (6)</td><td align="left">6 (6)</td><td align="left">8 (7)</td><td align="left">n.a</td><td char="." align="char">0.449</td></tr></tbody></table><table-wrap-foot><p><italic>ALS</italic> Amyotrophic Lateral Sclerosis; <italic>ALSFRS-R</italic> ALS Functional Rating Scale Revised; <italic>BDI-II</italic> Beck Depression Inventory -II; <italic>ECAS</italic> Edinburgh Cognitive and Behavioural ALS Screen; <italic>FA</italic> flail arm; <italic>FL</italic> flail leg; <italic>MMSE</italic> Mini Mental State Examination; <italic>HC</italic> Healthy Controls; <italic>χ2</italic> Chi-square test; <italic>UMN upper motor neuron</italic></p><p><sup>*</sup><italic>According to the King’s clinical staging system, the number of regions involved gives the stage</italic></p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Demographic, clinical, and neuropsychological measures of patients, divided into pseudobulbar (PSB) and non-pseudobulbar (nPSB), and healthy controls (HC); data are shown as mean (standard deviation) or count (percentage)
</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="left">Variables</th><th align="left">HC(n = 26)</th><th align="left">ALS(n = 27)</th><th align="left">PSB(n = 13)</th><th align="left">nPSB(n = 14)</th><th align="left">HC vs ALSp-value</th><th align="left">PSB vs nPSBp-value</th></tr></thead><tbody><tr><td align="left">Age, years</td><td align="left">58 (12)</td><td align="left">58 (9)</td><td align="left">56 (9)</td><td align="left">60 (10)</td><td align="left">0.947</td><td char="." align="char">0.271</td></tr><tr><td align="left">Education, years</td><td align="left">11 (4)</td><td align="left">11 (4)</td><td align="left">9 (3)</td><td align="left">12 (5)</td><td align="left">0.824</td><td char="." align="char">0.134</td></tr><tr><td align="left">Sex, male</td><td align="left">20 (76.9%)</td><td align="left">23 (85.2%)</td><td align="left">11 (84.6%)</td><td align="left">12 (85.7%)</td><td align="left">0.453</td><td char="." align="char">0.328</td></tr><tr><td align="left">Disease Duration, months</td><td align="left">n.a</td><td align="left">21 (21)</td><td align="left">16 (17)</td><td align="left">25 (25)</td><td align="left">n.a</td><td char="." align="char">0.24</td></tr><tr><td align="left">Disease onset(bulbar/upper limbs/lower limbs)</td><td align="left">n.a</td><td align="left">5/10/12</td><td align="left">4/5/4</td><td align="left">1/5/8</td><td align="left">n.a</td><td char="." align="char">0.157</td></tr><tr><td align="left">Disease phenotype(classic/bulbar/FL/FA/pyramidal)</td><td align="left">n.a</td><td align="left">3/3/5/5/11</td><td align="left">2/2/1/3/5</td><td align="left">1/1/4/2/6</td><td align="left">n.a</td><td char="." align="char">0.332</td></tr><tr><td align="left">ALSFRS-R total score</td><td align="left">n.a</td><td align="left">43 (3)</td><td align="left">42 (4)</td><td align="left">43 (3)</td><td align="left">n.a</td><td char="." align="char">0.773</td></tr><tr><td align="left">Bulbar subscore</td><td align="left">n.a</td><td align="left">11 (1)</td><td align="left">11 (1)</td><td align="left">12 (1)</td><td align="left">n.a</td><td char="." align="char">0.031</td></tr><tr><td align="left">Fine motor subscore</td><td align="left">n.a</td><td align="left">10 (2)</td><td align="left">10 (2)</td><td align="left">10 (2)</td><td align="left">n.a</td><td char="." align="char">0.599</td></tr><tr><td align="left">Gross motor subscore</td><td align="left">n.a</td><td align="left">10 (2)</td><td align="left">10 (2)</td><td align="left">9 (2)</td><td align="left">n.a</td><td char="." align="char">0.147</td></tr><tr><td align="left">Respiratory subscore</td><td align="left">n.a</td><td align="left">12 (0.4)</td><td align="left">12 (0.6)</td><td align="left">12 (0)</td><td align="left">n.a</td><td char="." align="char">0.221</td></tr><tr><td align="left">UMN score</td><td align="left">n.a</td><td align="left">8 (4)</td><td align="left">8 (4)</td><td align="left">8 (5)</td><td align="left">n.a</td><td char="." align="char">0.778</td></tr><tr><td align="left">King’s clinical staging (1/2/3)*</td><td align="left">n.a</td><td align="left">11/13/3</td><td align="left">5/5/3</td><td align="left">6/8/0</td><td align="left">n.a</td><td char="." align="char">0.305</td></tr><tr><td align="left">MMSE</td><td align="left">29(1)</td><td align="left">n.a</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char"/></tr><tr><td align="left">ECAS total score</td><td align="left">n.a</td><td align="left">88 (25)</td><td align="left">83 (22)</td><td align="left">92 (27)</td><td align="left">n.a</td><td char="." align="char">0.326</td></tr><tr><td align="left">Language</td><td align="left">n.a</td><td align="left">21 (5)</td><td align="left">20 (4)</td><td align="left">22 (5)</td><td align="left">n.a</td><td char="." align="char">0.441</td></tr><tr><td align="left">Verbal fluency</td><td align="left">n.a</td><td align="left">16 (7)</td><td align="left">16 (7)</td><td align="left">16 (8)</td><td align="left">n.a</td><td char="." align="char">0.993</td></tr><tr><td align="left">Executive functions</td><td align="left">n.a</td><td align="left">27 (11)</td><td align="left">24 (11)</td><td align="left">29 (11)</td><td align="left">n.a</td><td char="." align="char">0.269</td></tr><tr><td align="left">Memory</td><td align="left">n.a</td><td align="left">13 (5)</td><td align="left">12 (5)</td><td align="left">14 (5)</td><td align="left">n.a</td><td char="." align="char">0.205</td></tr><tr><td align="left">Visuospatial abilities</td><td align="left">n.a</td><td align="left">11 (1)</td><td align="left">10 (1)</td><td align="left">11 (1)</td><td align="left">n.a</td><td char="." align="char">0.214</td></tr><tr><td align="left">CNS-LS</td><td align="left">n.a</td><td align="left">12 (4)</td><td align="left">16 (2)</td><td align="left">9 (2)</td><td align="left">n.a</td><td char="." align="char"> &lt; 0.001</td></tr><tr><td align="left">Laughing</td><td align="left">n.a</td><td align="left">7 (3)</td><td align="left">9 (3)</td><td align="left">5 (1)</td><td align="left">n.a</td><td char="." align="char"> &lt; 0.001</td></tr><tr><td align="left">Crying</td><td align="left">n.a</td><td align="left">5 (2)</td><td align="left">6 (2)</td><td align="left">4 (1)</td><td align="left">n.a</td><td char="." align="char">0.003</td></tr><tr><td align="left">BDI-II</td><td align="left">n.a</td><td align="left">7 (6)</td><td align="left">6 (6)</td><td align="left">8 (7)</td><td align="left">n.a</td><td char="." align="char">0.449</td></tr></tbody></table></div>ALS Amyotrophic Lateral Sclerosis; ALSFRS-R ALS Functional Rating Scale Revised; BDI-II Beck Depression Inventory -II; ECAS Edinburgh Cognitive and Behavioural ALS Screen; FA flail arm; FL flail leg; MMSE Mini Mental State Examination; HC Healthy Controls; χ2 Chi-square test; UMN upper motor neuron*According to the King’s clinical staging system, the number of regions involved gives the stage</transformed-table></extracted-table></extracted-tables-set>